Bank Of America Corp Kiniksa Pharmaceuticals, Ltd. Transaction History

Bank Of America Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$17.63 - $21.74 $2.86 Million - $3.52 Million	161,962 Added 320.44%	212,505 $4.19 Million
Q4 2023 Feb 14, 2024	SELL	$14.37 - $19.07 $599,099 - $795,047	-41,691 Reduced 45.2%	50,543 $886,000
Q2 2023 Aug 14, 2023	SELL	$10.44 - $16.48 $1.01 Million - $1.6 Million	-96,785 Reduced 51.2%	92,234 $1.3 Million
Q1 2023 May 12, 2023	BUY	$10.7 - $15.79 $369,931 - $545,907	34,573 Added 22.39%	189,019 $2.03 Million
Q4 2022 Feb 10, 2023	BUY	$11.42 - $17.05 $1.47 Million - $2.19 Million	128,298 Added 490.66%	154,446 $2.31 Million
Q3 2022 Nov 14, 2022	BUY	$9.76 - $13.41 $5,651 - $7,764	579 Added 2.26%	26,148 $336,000
Q2 2022 Aug 12, 2022	SELL	$7.6 - $11.41 $49,346 - $74,085	-6,493 Reduced 20.25%	25,569 $247,000
Q1 2022 May 16, 2022	SELL	$9.3 - $12.37 $925,536 - $1.23 Million	-99,520 Reduced 75.63%	32,062 $319,000
Q4 2021 Feb 08, 2022	BUY	$10.39 - $15.15 $945,801 - $1.38 Million	91,030 Added 224.48%	131,582 $1.55 Million
Q3 2021 Nov 15, 2021	BUY	$11.39 - $16.23 $74,399 - $106,014	6,532 Added 19.2%	40,552 $462,000
Q2 2021 Sep 13, 2021	BUY	$13.22 - $19.09 $449,744 - $649,441	34,020 New	34,020 $474,000

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $687M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.